TNF and rheumatoid arthritis: The pharmacologic effect of inhibiting TNFα-driven inflammation explains the similar composite score response after the first six months of treatment, while the fact that this occurs in real-life patients adds to the evidence supporting the role of biosimilar bDMARDs in the modern management of RA patients.